$ANIK
Anika Therapeutics, Inc.

2017 Q4 Form 10-K Financial Statement

#000117184318001450 Filed on February 27, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $29.39M $27.18M $33.46M
YoY Change 2.3% 5.41% 25.89%
Cost Of Revenue $8.716M $6.250M $6.315M
YoY Change 15.61% 25.05% 4.12%
Gross Profit $20.17M $20.93M $22.03M
YoY Change -2.84% 0.69% 7.39%
Gross Profit Margin 68.63% 76.99% 65.82%
Selling, General & Admin $6.680M $4.823M $4.972M
YoY Change 21.68% 12.69% 16.85%
% of Gross Profit 33.12% 23.05% 22.57%
Research & Development $4.270M $5.842M $4.449M
YoY Change 44.26% 107.02% 59.35%
% of Gross Profit 21.17% 27.91% 20.2%
Depreciation & Amortization $1.070M $1.200M $1.010M
YoY Change 12.63% 36.36% 5.21%
% of Gross Profit 5.31% 5.73% 4.59%
Operating Expenses $10.94M $10.67M $9.421M
YoY Change 29.47% 50.17% 33.69%
Operating Profit $9.228M $10.27M $17.73M
YoY Change -25.02% -24.98% 31.61%
Interest Expense $140.0K $261.0K $16.00K
YoY Change 180.0% 180.65% -67.35%
% of Operating Profit 1.52% 2.54% 0.09%
Other Income/Expense, Net
YoY Change
Pretax Income $9.870M $10.53M $17.74M
YoY Change -22.83% -23.6% 31.25%
Income Tax $4.100M $3.643M $6.373M
% Of Pretax Income 41.54% 34.6% 35.92%
Net Earnings $8.067M $6.887M $11.37M
YoY Change -0.22% -23.07% 31.97%
Net Earnings / Revenue 27.45% 25.33% 33.98%
Basic Earnings Per Share $0.55 $0.47 $0.78
Diluted Earnings Per Share $0.53 $0.46 $0.76
COMMON SHARES
Basic Shares Outstanding 14.58M 14.59M
Diluted Shares Outstanding 15.14M 15.12M 15.04M

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $157.3M $152.7M $142.9M
YoY Change 26.04% 26.93% 28.05%
Cash & Equivalents $133.3M $127.0M $117.9M
Short-Term Investments $24.00M $25.80M $25.00M
Other Short-Term Assets $3.200M $2.300M $2.000M
YoY Change 52.38% 155.56% 66.67%
Inventory $22.04M $20.25M $17.58M
Prepaid Expenses
Receivables $23.83M $23.80M $30.45M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $206.3M $199.0M $192.9M
YoY Change 21.06% 23.57% 24.73%
LONG-TERM ASSETS
Property, Plant & Equipment $56.18M $53.97M $52.27M
YoY Change 7.43% 5.71% 6.25%
Goodwill $8.218M $8.104M $7.836M
YoY Change 13.92% 5.38% 3.54%
Intangibles $10.64M $10.74M $10.63M
YoY Change 3.99% -3.88% -5.62%
Long-Term Investments
YoY Change
Other Assets $1.254M $1.283M $1.400M
YoY Change 1717.39% 1183.0% 1300.0%
Total Long-Term Assets $76.29M $74.10M $72.12M
YoY Change 9.29% 5.87% 5.92%
TOTAL ASSETS
Total Short-Term Assets $206.3M $199.0M $192.9M
Total Long-Term Assets $76.29M $74.10M $72.12M
Total Assets $282.6M $273.1M $265.0M
YoY Change 17.64% 18.21% 18.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.747M $5.189M $5.465M
YoY Change 192.97% 166.24% 65.91%
Accrued Expenses $6.326M $6.516M $5.673M
YoY Change -2.62% 20.15% -14.54%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.07M $11.71M $13.44M
YoY Change 48.57% 54.24% 27.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $660.0K $545.0K $422.0K
YoY Change -68.96% -78.68% -64.02%
Total Long-Term Liabilities $660.0K $545.0K $422.0K
YoY Change -68.96% -78.68% -64.02%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.07M $11.71M $13.44M
Total Long-Term Liabilities $660.0K $545.0K $422.0K
Total Liabilities $13.73M $12.25M $13.86M
YoY Change 25.7% 20.75% 18.53%
SHAREHOLDERS EQUITY
Retained Earnings $199.5M $191.4M $184.6M
YoY Change 18.61% 19.56% 22.08%
Common Stock $68.76M $66.89M $65.32M
YoY Change 11.12% 10.53% 9.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $263.5M $253.3M $244.1M
YoY Change
Total Liabilities & Shareholders Equity $282.6M $273.1M $265.0M
YoY Change 17.64% 18.21% 18.98%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income $8.067M $6.887M $11.37M
YoY Change -0.22% -23.07% 31.97%
Depreciation, Depletion And Amortization $1.070M $1.200M $1.010M
YoY Change 12.63% 36.36% 5.21%
Cash From Operating Activities $6.980M $12.10M $6.270M
YoY Change 14.99% 6.89% -1111.29%
INVESTING ACTIVITIES
Capital Expenditures -$2.470M -$2.590M -$2.240M
YoY Change 76.43% -5.47% -35.07%
Acquisitions
YoY Change
Other Investing Activities $1.750M -$750.0K -$5.750M
YoY Change 0.0% -400.0% -1250.0%
Cash From Investing Activities -$720.0K -$3.340M -$7.990M
YoY Change -305.71% 34.14% 170.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 100.0K 170.0K
YoY Change -100.0% 42.86% -254.55%
NET CHANGE
Cash From Operating Activities 6.980M 12.10M 6.270M
Cash From Investing Activities -720.0K -3.340M -7.990M
Cash From Financing Activities 0.000 100.0K 170.0K
Net Change In Cash 6.260M 8.860M -1.550M
YoY Change -2.8% -0.45% -57.88%
FREE CASH FLOW
Cash From Operating Activities $6.980M $12.10M $6.270M
Capital Expenditures -$2.470M -$2.590M -$2.240M
Free Cash Flow $9.450M $14.69M $8.510M
YoY Change 26.51% 4.48% 200.71%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
2318000
CY2016Q4 anik Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
227000
CY2017Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
419000
CY2016Q4 anik Accrued Research Grants Current
AccruedResearchGrantsCurrent
463000
CY2017Q4 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
4132000
CY2016Q4 anik Accumulated Currency Translation Adjustment
AccumulatedCurrencyTranslationAdjustment
5497000
CY2017 anik Allowance For Doubtful Accounts Receivable Translation Adjustments
AllowanceForDoubtfulAccountsReceivableTranslationAdjustments
117000
CY2016 anik Allowance For Doubtful Accounts Receivable Translation Adjustments
AllowanceForDoubtfulAccountsReceivableTranslationAdjustments
-9000
CY2015 anik Allowance For Doubtful Accounts Receivable Translation Adjustments
AllowanceForDoubtfulAccountsReceivableTranslationAdjustments
-15000
CY2017 anik Buildtosuite Lease Agreement
BuildtosuiteLeaseAgreement
0
CY2016 anik Buildtosuite Lease Agreement
BuildtosuiteLeaseAgreement
1723000
CY2015 anik Buildtosuite Lease Agreement
BuildtosuiteLeaseAgreement
30000
CY2017 anik Deferred Income Tax Expense Benefit Foreign And Domestic Net
DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet
-990000
CY2016 anik Deferred Income Tax Expense Benefit Foreign And Domestic Net
DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet
-226000
CY2015 anik Deferred Income Tax Expense Benefit Foreign And Domestic Net
DeferredIncomeTaxExpenseBenefitForeignAndDomesticNet
-960000
CY2017 anik Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
600000
CY2016 anik Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
600000
CY2015 anik Defined Contribution Plan Employer Matching Contribution Amount
DefinedContributionPlanEmployerMatchingContributionAmount
400000
CY2017 anik Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent
EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent
0.006
CY2016 anik Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent
EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent
0.005
CY2015 anik Effective Income Tax Reconciliation Nondeductible Expenses Permanent Items Percent
EffectiveIncomeTaxReconciliationNondeductibleExpensesPermanentItemsPercent
-0.003
CY2017Q4 anik Operating Leases Future Minimum Payments Due In Five Years And Thereafter
OperatingLeasesFutureMinimumPaymentsDueInFiveYearsAndThereafter
1311000
CY2017 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2016 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2015 anik Percentage Of Net Revenue
PercentageOfNetRevenue
1
CY2017 anik Schedule Of Sharebased Compensation Exercisable Stock Options And Stock Appreciation Rights Award Activity Table Text Bloc
ScheduleOfSharebasedCompensationExercisableStockOptionsAndStockAppreciationRightsAwardActivityTableTextBloc
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="border-collapse: collapse; min-; min-width: 700px;" cellspacing="0" cellpadding="0" align="center"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Outstanding</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average<br /> Exercise Price</td> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</td> <td colspan="3" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Weighted Average <br /> Remaining Term<br /> (in years)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Incentive stock options</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,472</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.12</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 2%; font-size: 10pt">&nbsp;</td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> <td style="width: 12%; font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.3</div></td> <td style="width: 1%; font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Nonqualified stock options</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">374,211</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20.18</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.3</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Performance options</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">32,598</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">38.79</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.7</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">SAR's</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,250</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">$</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.36</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt">&nbsp;</td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> <td style="font-size: 10pt; text-align: right"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.1</div></td> <td style="font-size: 10pt; text-align: left">&nbsp;</td> </tr> </table></div>
CY2017 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
500000
CY2016 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodTotalIntrinsicValue
2100000
CY2017Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue
27600000
CY2016Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingIntrinsicValue
22300000
CY2017 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingWeightedAverageRemainingContractualTerm
P7Y
CY2016Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
26.15
CY2015Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
18.75
CY2017Q4 anik Share Based Compensation Arrangement By Share Based Payment Award Options And Stock Appreciation Rights Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndStockAppreciationRightsWeightedAverageExercisePrice
33.70
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod
17941
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriod
74815
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6326000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6496000
CY2017Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
448000
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice
20.56
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Exercises In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExercisesInPeriodWeightedAverageExercisePrice
15.46
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod
589
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriod
3310
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice
32.86
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Expirations In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsExpirationsInPeriodWeightedAverageExercisePrice
11.37
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod
74527
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriod
58841
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice
45.56
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Forfeitures In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsForfeituresInPeriodWeightedAverageExercisePrice
30.05
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod
440688
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriod
354275
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice
50.22
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Grants In Period Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsGrantsInPeriodWeightedAverageExercisePrice
40.77
CY2016Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
979569
CY2015Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
762260
CY2017Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Outstanding Number
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsOutstandingNumber
1327200
CY2017Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue
22000000
CY2016Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAggregateIntrinsicValue
16700000
CY2017Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested And Expected To Vest Outstanding Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
33.70
CY2017 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue
2100000
CY2016 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Appreciation Rights Vested In Period Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockAppreciationRightsVestedInPeriodFairValue
1300000
CY2017Q4 anik Sharebased Compensation Arrangement By Sharebased Payment Award Options And Stock Ppreciation Rights Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAndStockPpreciationRightsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
27600000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6747000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2303000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
23825000
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
27598000
CY2017Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6326000
CY2016Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6496000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
802000
CY2017Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
CY2016Q4 us-gaap Accrued Rent Current
AccruedRentCurrent
231000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20190000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
26777000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4784000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7317000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
68617000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61735000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
0
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1891000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2225000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3392000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5807000
CY2016 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
647000
CY2015 us-gaap Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation
AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation
847000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5807000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3392000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2225000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
194000
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
167000
CY2014Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
147000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
1914000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1914000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
194000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
6000
CY2016 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
16000
CY2015 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
3000
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000
CY2016 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2015 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1100000
CY2017Q4 us-gaap Assets
Assets
282617000
CY2016Q4 us-gaap Assets
Assets
240246000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
206327000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
170440000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
0
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1257000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1949000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133256000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
104261000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
110707000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
100156000
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6393000
CY2016Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
69102000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
28995000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6446000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
10551000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14688000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14627000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14688000
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14627000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
147000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
146000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
34349000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
31879000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
28604000
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Concentration of Credit Risk and Significant Customers</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> significant off-balance sheet risks related to foreign exchange contracts, option contracts, or other foreign hedging arrangements. The Company&#x2019;s cash equivalents and investments are held with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> major international financial institutions.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited.</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">As of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> DePuy Synthes Mitek Sports Medicine, a division of DePuy Orthopaedics, Inc. (&#x201c;Mitek&#x201d;), represented <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">68%</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66%,</div> respectively, of the Company&#x2019;s accounts receivable balance, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> other single customer accounted for more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10%</div> of accounts receivable in either period.</div></div></div></div></div></div></div></div>
CY2017 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
CY2016 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
CY2015 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
1
CY2017Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
CY2016Q4 us-gaap Construction Payable Current
ConstructionPayableCurrent
804000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27364000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
24027000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
21053000
CY2017Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8716000
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6250000
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6315000
CY2017Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6083000
CY2016Q4 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7539000
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4998000
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6065000
CY2016Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
5425000
CY2017 us-gaap Costs And Expenses
CostsAndExpenses
67691000
CY2016 us-gaap Costs And Expenses
CostsAndExpenses
52772000
CY2015 us-gaap Costs And Expenses
CostsAndExpenses
44865000
CY2017Q4 us-gaap Cumulative Effect Of New Accounting Principle In Period Of Adoption
CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
248000
CY2017 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
12608000
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
14982000
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
14572000
CY2017 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
31000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
302000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
249000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
15376000
CY2016 us-gaap Depreciation
Depreciation
2700000
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-33000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4769000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
4760000
CY2017Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
740000
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
640000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
959000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
18549000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
18456000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2737000
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3265000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3635000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-426000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-70000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-370000
CY2017 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-496000
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-72000
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
-557000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1198000
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-65000
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-747000
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
10162000
CY2016Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
11308000
CY2017Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
5393000
CY2016Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
6548000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-68000
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-84000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
1253000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2309000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1882000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
496000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
308000
CY2017Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
265000
CY2016Q4 us-gaap Deferred Tax Assets Unrealized Currency Losses
DeferredTaxAssetsUnrealizedCurrencyLosses
677000
CY2017Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
2743000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
2932000
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
5393000
CY2016Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6548000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
7419000
CY2016Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
8376000
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.05
CY2017 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1.4
CY2017 us-gaap Depreciation
Depreciation
3300000
CY2015 us-gaap Depreciation
Depreciation
2700000
CY2017 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4290000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3734000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3775000
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.18
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.22
CY2015 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.06
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.55
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.47
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.38
CY2016Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.61
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.59
CY2016Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.46
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.11
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.15
CY2015 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.01
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.46
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.76
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.37
CY2016Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.54
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
CY2016Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.45
CY2017 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
349000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-138000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-208000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.311
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.36
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.363
CY2017Q4 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.049
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.028
CY2016 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.029
CY2015 us-gaap Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities
EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities
0.029
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.005
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.001
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.048
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
0.007
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
0.001
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Investment
EffectiveIncomeTaxRateReconciliationTaxCreditsInvestment
0
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.014
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.009
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.004
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2893000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3089000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-13439000
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-12482000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3100000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1000000
CY2017Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1000000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
700000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-300000
CY2015 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-400000
CY2017 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-150000
CY2016 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2015 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
CY2017Q4 us-gaap Goodwill
Goodwill
8218000
CY2016Q4 us-gaap Goodwill
Goodwill
7214000
CY2015Q4 us-gaap Goodwill
Goodwill
7482000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
46202000
CY2017 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
1004000
CY2016 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-268000
CY2017Q4 us-gaap Gross Profit
GrossProfit
20168000
CY2017Q3 us-gaap Gross Profit
GrossProfit
20928000
CY2017Q2 us-gaap Gross Profit
GrossProfit
22025000
CY2017Q1 us-gaap Gross Profit
GrossProfit
17298000
CY2016Q4 us-gaap Gross Profit
GrossProfit
20757000
CY2016Q3 us-gaap Gross Profit
GrossProfit
20785000
CY2016Q2 us-gaap Gross Profit
GrossProfit
20510000
CY2016Q1 us-gaap Gross Profit
GrossProfit
16853000
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
CY2015 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
697000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
48446000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
50181000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
48608000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
50870000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
48254000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-2244000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
689000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-354000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
14386000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18323000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
17496000
CY2017Q4 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
-2300000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
15088000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
22826000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
12724000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
8952000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
8615000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
6895000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3890000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5059000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5625000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2674000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6201000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4996000
CY2017 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
367000
CY2016 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-3552000
CY2015 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
5484000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-605000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1566000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-199000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6521000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1738000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2939000
CY2017 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-708000
CY2016 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
16000
CY2015 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-109000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1454000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
898000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-89000
CY2017Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
28206000
CY2017Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10635000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
10227000
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
473000
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
263000
CY2015 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
120000
CY2017Q4 us-gaap Inventory Adjustments
InventoryAdjustments
1700000
CY2016Q4 us-gaap Inventory Adjustments
InventoryAdjustments
900000
CY2017Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4677000
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4540000
CY2017Q4 us-gaap Inventory Net
InventoryNet
22035000
CY2016Q4 us-gaap Inventory Net
InventoryNet
15983000
CY2017Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11296000
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5884000
CY2017Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6062000
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5559000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
30758000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
8067000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
6887000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
11369000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
5493000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
8085000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1800000
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1300000
CY2015 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
1300000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
282617000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240246000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13073000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8799000
CY2017 us-gaap Inventory Write Down
InventoryWriteDown
695000
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
654000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
210000
CY2017Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24000000
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
20500000
CY2017 us-gaap Nature Of Operations
NatureOfOperations
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Nature of Business</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Anika Therapeutics, Inc. (the &#x201c;Company&#x201d;) is a global, integrated orthopedic medicines company committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative tissue repair. The Company has over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> decades of global expertise developing, manufacturing, and commercializing products based on the Company&#x2019;s proprietary Hyaluronic Acid (&#x201c;HA&#x201d;) technology. The Company&#x2019;s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0; background-color: white">The Company is subject to risks common to companies in the biotechnology and medical device industries including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, development by the Company or its competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, commercialization of existing and new products, and compliance with U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and foreign regulations and approval requirements, as well as the ability to grow the Company&#x2019;s business through appropriate commercial strategies.</div></div>
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
314000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-23993000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1074000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-12480000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6763000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30226000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
40812000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
24448000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
39911000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
31816000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
32547000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
45729000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
50607000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
48134000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10583000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1879000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1673000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1924000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1916000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1880000
CY2017Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
4000000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
248000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
880000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1254000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
69000
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
2533000
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-668000
CY2015 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2154000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2500000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-700000
CY2015 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2200000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2154000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-668000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
2533000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
660000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2126000
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
25000000
CY2015 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
CY2017 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
45000000
CY2016 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
39249000
CY2015 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
45251000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8980000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14014000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9225000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1250000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3211000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2098000
CY2017 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
41500000
CY2016 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
46500000
CY2015 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
24250000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
314000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1007000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1074000
CY2017Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2016Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
0
CY2017 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
9800000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
76373000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
79073000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
56183000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
52296000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1609000
CY2016 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
52000
CY2015 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
38000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18787000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10732000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8987000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
199511000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
168209000
CY2017 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0"><div style="display: inline; font-style: italic;">Product Revenue</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">Revenues from product sales are recognized when title and risk of loss have passed to the customer, which is typically upon shipment to the customer. Amounts billed or collected prior to recognition of revenue are classified as deferred revenue. When determining whether risk of loss has transferred to customers on product sales, or if the sales price is fixed or determinable, the Company evaluates both the contractual terms and conditions of its distribution and supply agreements as well as its business practices. </div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></div> <!-- Field: Page; Sequence: 52; Value: 1 --> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0"></div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0"><div style="display: inline; background-color: white">Product revenue also includes royalties. Royalty revenue is based on distributors&#x2019; sales and is recognized in the same period distributors record their sale of products manufactured by the Company. On a quarterly basis the Company records royalty revenue based upon sales provided to it by its distributor customers. </div></div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0"><div style="display: inline; background-color: white">Pursuant to the Health Care and Education Reconciliation Act of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2010,</div> in conjunction with the Patient Protection and Affordable Care Act, a medical device excise tax (&#x201c;MDET&#x201d;) became effective on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2013 </div>for sales of certain medical devices. Some of the Company&#x2019;s product sales are subject to the provisions of the MDET. The Company elected to recognize any amounts related to the MDET under the gross method as allowed under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45.</div> Amounts included in revenues and costs of goods sold for the MDET in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> were immaterial. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> amounts reported for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> as the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.3%</div> MDET has been suspended by Congress from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2016 </div>through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2020.</div> </div></div></div></div></div></div></div></div></div>
CY2017 us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0"><div style="display: inline; font-style: italic;">Licensing, Milestone and Contract Revenue</div></div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">Licensing, milestone and contract revenue consists of revenue recognized on initial and milestone payments, as well as contractual amounts received from partners. The Company&#x2019;s business strategy includes entering into collaborative license, development, and/or supply agreements with partners for the development and commercialization of the Company&#x2019;s products. Under the milestone method, the Company recognizes a consideration that is contingent upon the achievement of a milestone in its entirety as revenue in the period in which the milestone is achieved only if the milestone is substantive in its entirety. A milestone is considered substantive when it meets all of the following criteria:</div> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 24px">&nbsp;</td> <td style="width: 24px"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div></div></td> <td><div style="display: inline; font-size: 10pt">The consideration is commensurate with either the entity&#x2019;s performance to achieve the milestone or the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#x2019;s performance to achieve the milestone;</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 24px">&nbsp;</td> <td style="width: 24px"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div></div></td> <td><div style="display: inline; font-size: 10pt">The consideration relates solely to past performance; and</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <table cellspacing="0" cellpadding="0" style="; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 24px">&nbsp;</td> <td style="width: 24px"><div style="display: inline; font-size: 10pt"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div></div></td> <td><div style="display: inline; font-size: 10pt">The consideration is reasonable relative to all of the deliverables and payment terms within the arrangement.</div></td> </tr> </table> <div style=" font-size: 10pt; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">A milestone is defined as an event (i) that can only be achieved based in whole or in part on either the entity&#x2019;s performance or on the occurrence of a specific outcome resulting from the entity&#x2019;s performance, (ii) for which there is substantive uncertainty at the date the arrangement is entered into that the event will be achieved, and (iii) that would result in additional payments being due to the Company. Non substantive milestones are recognized when there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> further obligations by the Company.</div> <div style=" font-size: 10pt; text-indent: 0.55in; margin: 0pt 0">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The terms of the agreements typically include non-refundable license fees, funding of research and development, and payments based upon achievement of certain milestones. The Company adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> <div style="display: inline; font-style: italic;">Revenue Recognition</div> in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2011, </div>which amended ASC Subtopic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> <div style="display: inline; font-style: italic;">Multiple Element Arrangements</div> (&#x201c;ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25&#x201d;</div>) to require the establishment of a selling price hierarchy for determining the allocable selling price of an item. Under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25,</div> as amended by ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2009</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,</div> in order to account for an element as a separate unit of accounting, the element must have objective and reliable evidence of selling price of the undelivered elements. In general, non-refundable up-front fees and milestone payments that do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> relate to other elements are recognized as revenue over the term of the arrangement as the Company completes its performance obligations.</div></div></div></div></div></div></div></div>
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
107783000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
102932000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
87696000
CY2017Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
28884000
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
27178000
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
28340000
CY2017Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23381000
CY2016Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
28296000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
25783000
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
26575000
CY2016Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
22278000
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
113420000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
103379000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
92999000
CY2017Q4 us-gaap Sales Revenue Net
SalesRevenueNet
29388000
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
27184000
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
33462000
CY2017Q1 us-gaap Sales Revenue Net
SalesRevenueNet
23386000
CY2016Q4 us-gaap Sales Revenue Net
SalesRevenueNet
28726000
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
25789000
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
26581000
CY2016Q1 us-gaap Sales Revenue Net
SalesRevenueNet
22283000
CY2017 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
5637000
CY2016 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
447000
CY2015 us-gaap Sales Revenue Services Net
SalesRevenueServicesNet
5303000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y182D
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21540000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
18013000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14825000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
5807000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
3392000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
2225000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y182D
CY2015 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1074000
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1007000
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
314000
CY2016 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
25000000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
263491000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
222773000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
178098000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
210848000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-indent: -0.55in; margin: 0pt 0 0pt 0.55in"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-size: 10pt; margin: 0pt 0 0pt 0.55in">&nbsp;</div> <div style=" font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</div></div></div></div></div></div></div></div>
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
493000
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
434000
CY2015 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
387000
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15068000
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15116000
CY2015 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15321000
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15141000
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15115000
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15044000
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15043000
CY2016Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14979000
CY2016Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15077000
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15111000
CY2016Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15307000
CY2017Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14596000
CY2017Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14579000
CY2017Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14588000
CY2017Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14576000
CY2016Q4 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14538000
CY2016Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14625000
CY2016Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14679000
CY2016Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
14875000
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14575000
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14682000
CY2015 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14934000

Files In Submission

Name View Source Status
0001171843-18-001450-index-headers.html Edgar Link pending
0001171843-18-001450-index.html Edgar Link pending
0001171843-18-001450.txt Edgar Link pending
0001171843-18-001450-xbrl.zip Edgar Link pending
anik-20171231.xml Edgar Link completed
anik-20171231.xsd Edgar Link pending
anik-20171231_cal.xml Edgar Link unprocessable
anik-20171231_def.xml Edgar Link unprocessable
anik-20171231_lab.xml Edgar Link unprocessable
anik-20171231_pre.xml Edgar Link unprocessable
exh_211.htm Edgar Link pending
exh_231.htm Edgar Link pending
exh_232.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
f10k_022618p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pg27_graph.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending